World-Renowned Alzheimer's Expert Prof. Steven Arnold Joins NeuroSense SAB [Yahoo! Finance]
World-Renowned Alzheimer's Expert Prof. Steven Arnold Joins NeuroSense SAB
NeuroSense Therapeutics (NASDAQ:NRSN) was upgraded by analysts at
Wall S
NeuroSense Therapeutics (NASDAQ:NRSN) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $14.00 price target on the stock.
NeuroSense Confirms Favorable Safety and Tolerability of PrimeC in an Alzheimer's Phase 2 Study [Yahoo! Finance]